Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy February 9, 2026
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program February 3, 2026
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care February 2, 2026
